Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Neoplasms of the CNS

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 261 articles:
HTML format



Single Articles


    June 2024
  1. LIU ZY, Tang F, Wang J, Yang JZ, et al
    Serum beta2-microglobulin acts as a biomarker for severity and prognosis in glioma patients: a preliminary clinical study.
    BMC Cancer. 2024;24:692.
    PubMed     Abstract available


    May 2024
  2. ZHANG LY, Guo W, Du HZ, Pan H, et al
    Brachytherapy in craniopharyngiomas: a systematic review and meta-analysis of long-term follow-up.
    BMC Cancer. 2024;24:637.
    PubMed     Abstract available


  3. AZIMI P, Yazdanian T, Ahmadiani A
    mRNA markers for survival prediction in glioblastoma multiforme patients: a systematic review with bioinformatic analyses.
    BMC Cancer. 2024;24:612.
    PubMed     Abstract available


  4. WANG J, Wang G, Cheng L, Zhu H, et al
    Preoperative peripheral inflammatory markers are predictors of postoperative central diabetes insipidus in craniopharyngioma patients: a retrospective study.
    BMC Cancer. 2024;24:572.
    PubMed     Abstract available


    April 2024
  5. KUMTHEKAR P, Lyleroehr M, Lacson L, Lukas RV, et al
    A qualitative evaluation of factors influencing Tumor Treating fields (TTFields) therapy decision making among brain tumor patients and physicians.
    BMC Cancer. 2024;24:527.
    PubMed     Abstract available


  6. LIU C, Liu F, Nie D, Xiao Y, et al
    Gut microbiota composition and metabolic characteristics in patients with Craniopharyngioma.
    BMC Cancer. 2024;24:521.
    PubMed     Abstract available


  7. DVORAKOVA K, Skarkova V, Vitovcova B, Soukup J, et al
    Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients.
    BMC Cancer. 2024;24:509.
    PubMed     Abstract available


  8. SHI MX, Ding X, Tang L, Cao WJ, et al
    PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis.
    BMC Cancer. 2024;24:504.
    PubMed     Abstract available


  9. ORESKOVIC D, Madero Pohlen A, Cvitkovic I, Alen JF, et al
    Chronic hyperglycemia and intracranial meningiomas.
    BMC Cancer. 2024;24:488.
    PubMed     Abstract available


  10. DENG MY, da Silva AS, Goller PC, Konig L, et al
    Plasma extracellular vesicles in meningioma patients following radiotherapy as liquid biopsy- a prospective explorative biomarker study (ARO 2023-05/AG-NRO-07).
    BMC Cancer. 2024;24:449.
    PubMed     Abstract available


  11. KONG C, Yin X, Zou J, Ma C, et al
    The application of different machine learning models based on PET/CT images and EGFR in predicting brain metastasis of adenocarcinoma of the lung.
    BMC Cancer. 2024;24:454.
    PubMed     Abstract available


  12. CHEN M, Li R, Kong Y, Shi L, et al
    Rational and design of prophylactic cranial irradiation (PCI) and brain MRI surveillance versus brain MRI surveillance alone in patients with limited-stage small cell lung cancer achieving complete remission (CR) of tumor after chemoradiotherapy: a mu
    BMC Cancer. 2024;24:429.
    PubMed     Abstract available


    March 2024
  13. WANG G, Ren X, Li J, Cui R, et al
    High expression of RTEL1 predicates worse progression in gliomas and promotes tumorigenesis through JNK/ELK1 cascade.
    BMC Cancer. 2024;24:385.
    PubMed     Abstract available


  14. ZHANG W, Blank A, Kremenetskaia I, Nitzsche A, et al
    CD13 expression affects glioma patient survival and influences key functions of human glioblastoma cell lines in vitro.
    BMC Cancer. 2024;24:369.
    PubMed     Abstract available


  15. QI H, Hou Y, Zheng Z, Zheng M, et al
    Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.
    BMC Cancer. 2024;24:362.
    PubMed     Abstract available


  16. MA Y, Gong Y, Qiu Q, Ma C, et al
    Research on multi-model imaging machine learning for distinguishing early hepatocellular carcinoma.
    BMC Cancer. 2024;24:363.
    PubMed     Abstract available


  17. HUANG Y, Wu Z, Peng Z, Liu A, et al
    Hsa_circ_0004872 alleviates meningioma progression by sponging miR-190a-3p/PTEN signaling.
    BMC Cancer. 2024;24:345.
    PubMed     Abstract available


  18. ROUTMAN DM, Jusue-Torres I, Brown PD, Trifiletti DM, et al
    Pre-operative vs. post-operative stereotactic radiosurgery for operative metastatic brain tumors: study protocol for a phase III clinical trial.
    BMC Cancer. 2024;24:332.
    PubMed     Abstract available


  19. MENG J, Qian W, Yang Z, Gong L, et al
    p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme.
    BMC Cancer. 2024;24:317.
    PubMed     Abstract available


    February 2024
  20. SUN L, Jin X, Xie L, Xu G, et al
    Retraction Note: Swainsonine represses glioma cell proliferation, migration and invasion by reduction of miR-92a expression.
    BMC Cancer. 2024;24:275.
    PubMed    


  21. QIAO W, Wang Y, Luo C, Wu J, et al
    Development of preoperative and postoperative models to predict recurrence in postoperative glioma patients: a longitudinal cohort study.
    BMC Cancer. 2024;24:274.
    PubMed     Abstract available


  22. KINO S, Kanamori M, Shimoda Y, Niizuma K, et al
    Distinguishing IDH mutation status in gliomas using FTIR-ATR spectra of peripheral blood plasma indicating clear traces of protein amyloid aggregation.
    BMC Cancer. 2024;24:222.
    PubMed     Abstract available


  23. BEN-ZION BERLINER M, Yust-Katz S, Lavie I, Goldberg Y, et al
    Central nervous system metastases in breast cancer patients with germline BRCA pathogenic variants compared to non-carriers: a matched-pair analysis.
    BMC Cancer. 2024;24:219.
    PubMed     Abstract available


  24. LI G, Ma L, Feng C, Yin H, et al
    MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by suppressing SDC1 in glioblastoma.
    BMC Cancer. 2024;24:220.
    PubMed     Abstract available


  25. BOCCACINO JM, Dos Santos Peixoto R, Fernandes CFL, Cangiano G, et al
    Integrated transcriptomics uncovers an enhanced association between the prion protein gene expression and vesicle dynamics signatures in glioblastomas.
    BMC Cancer. 2024;24:199.
    PubMed     Abstract available


  26. SHIM YB, Oh BC, Lee EK, Park MH, et al
    Comparison of partitioned survival modeling with state transition modeling approaches with or without consideration of brain metastasis: a case study of Osimertinib versus pemetrexed-platinum.
    BMC Cancer. 2024;24:189.
    PubMed     Abstract available


  27. PHAM CP, Nguyen TTH, Do AT, Nguyen TK, et al
    A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.
    BMC Cancer. 2024;24:176.
    PubMed     Abstract available


  28. LIAO L, Tang J, Hong Z, Jiang W, et al
    The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study.
    BMC Cancer. 2024;24:164.
    PubMed     Abstract available


    January 2024
  29. ZHANG X, Li Y, Zhang G, Ma C, et al
    Temporal trend in hospitalizations for malignant neoplasm and benign neoplasm: a nationwide study, China, 2004-2020.
    BMC Cancer. 2024;24:154.
    PubMed     Abstract available


  30. VAN TILBURG CM, Kilburn LB, Perreault S, Schmidt R, et al
    LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
    BMC Cancer. 2024;24:147.
    PubMed     Abstract available


  31. YU W, Zhou M, Niu H, Li J, et al
    Prognostic marker CXCL5 in glioblastoma polyformis and its mechanism of immune invasion.
    BMC Cancer. 2024;24:140.
    PubMed     Abstract available


  32. YAO B, Wang H, Wu X, Wang C, et al
    A system review of central nervous system tumors on children in China: epidemiology and clinical characteristics.
    BMC Cancer. 2024;24:138.
    PubMed     Abstract available


  33. HEUER S, Burghaus I, Gose M, Kessler T, et al
    PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma.
    BMC Cancer. 2024;24:135.
    PubMed     Abstract available


  34. LU Y, Liao L, Du K, Mo J, et al
    Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma.
    BMC Cancer. 2024;24:133.
    PubMed     Abstract available


  35. LIU JS, Cai YX, He YZ, Xu J, et al
    Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
    BMC Cancer. 2024;24:123.
    PubMed     Abstract available


  36. QIAN J, He Z, Wu Y, Li H, et al
    Analysis of the efficacy of upfront brain radiotherapy versus deferred radiotherapy for EGFR/ALK-positive non-small cell lung cancer with brain metastases: a retrospective study.
    BMC Cancer. 2024;24:117.
    PubMed     Abstract available


  37. YANG W, Han Y, He C, Zhong S, et al
    Association between psychiatric disorders and glioma risk: evidence from Mendelian randomization analysis.
    BMC Cancer. 2024;24:118.
    PubMed     Abstract available


  38. ZHU X, Liu Y, Guo W, Liang Q, et al
    Epidemiology, characteristics, and prognostic factors of lymphoplasmacyte-rich meningioma: a systematic literature review.
    BMC Cancer. 2024;24:110.
    PubMed     Abstract available


  39. LI L, Xia S, Zhao Z, Deng L, et al
    EMP3 as a prognostic biomarker correlates with EMT in GBM.
    BMC Cancer. 2024;24:89.
    PubMed     Abstract available


  40. ZUCHEGNA C, Leone S, Romano A, Porcellini A, et al
    KRAS is a molecular determinant of platinum responsiveness in glioblastoma.
    BMC Cancer. 2024;24:77.
    PubMed     Abstract available


  41. MASTALL M, Roth P, Bink A, Fischer Maranta A, et al
    A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
    BMC Cancer. 2024;24:82.
    PubMed     Abstract available


  42. BHASKARAN D, Savage J, Patel A, Collinson F, et al
    A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial.
    BMC Cancer. 2024;24:83.
    PubMed     Abstract available


  43. HUANG CY, Bai MH, Shen JW, Sun QQ, et al
    Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial.
    BMC Cancer. 2024;24:57.
    PubMed     Abstract available


  44. SUN Y, Liu P, Wang Z, Zhang H, et al
    Efficacy and indications of gamma knife radiosurgery for recurrent low-and high-grade glioma.
    BMC Cancer. 2024;24:37.
    PubMed     Abstract available


  45. CRUCITTA S, Pasqualetti F, Gonnelli A, Ruglioni M, et al
    IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients.
    BMC Cancer. 2024;24:31.
    PubMed     Abstract available


  46. MOHAJERANI F, Tehrankhah ZM, Rahmani S, Afsordeh N, et al
    CLEC19A overexpression inhibits tumor cell proliferation/migration and promotes apoptosis concomitant suppression of PI3K/AKT/NF-kappaB signaling pathway in glioblastoma multiforme.
    BMC Cancer. 2024;24:19.
    PubMed     Abstract available


  47. OUDIN A, Moreno-Sanchez PM, Baus V, Niclou SP, et al
    Magnetic resonance imaging-guided intracranial resection of glioblastoma tumors in patient-derived orthotopic xenografts leads to clinically relevant tumor recurrence.
    BMC Cancer. 2024;24:3.
    PubMed     Abstract available


  48. ZHAO S, Zhang M, Zhang Q, Wu J, et al
    Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial.
    BMC Cancer. 2024;24:6.
    PubMed     Abstract available


    December 2023
  49. DAI L, Zhou P, Lyu L, Jiang S, et al
    Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma.
    BMC Cancer. 2023;23:1249.
    PubMed     Abstract available


  50. ZHANG K, Zhang T, Guo Z, Zhao F, et al
    Adding simultaneous integrated boost to whole brain radiation therapy improved intracranial tumour control and minimize radiation-induced brain injury risk for the treatment of brain metastases.
    BMC Cancer. 2023;23:1240.
    PubMed     Abstract available


  51. ADEGBOYEGA B, Joseph A, Alabi A, Omomila J, et al
    Patient reported outcomes following whole brain radiotherapy in patients with brain metastases in NSIA-LUTH Cancer Center.
    BMC Cancer. 2023;23:1233.
    PubMed     Abstract available


  52. BAI J, He M, Gao E, Yang G, et al
    Radiomic texture analysis based on neurite orientation dispersion and density imaging to differentiate glioblastoma from solitary brain metastasis.
    BMC Cancer. 2023;23:1231.
    PubMed     Abstract available


    November 2023
  53. SENRUNG A, Tripathi T, Yadav J, Janjua D, et al
    In vivo antiangiogenic effect of nimbolide, trans-chalcone and piperine for use against glioblastoma.
    BMC Cancer. 2023;23:1173.
    PubMed     Abstract available


  54. ZHANG Y, Wu X, Zhu J, Lu R, et al
    Knockdown of SLC39A14 inhibits glioma progression by promoting erastin-induced ferroptosis SLC39A14 knockdown inhibits glioma progression.
    BMC Cancer. 2023;23:1120.
    PubMed     Abstract available


    October 2023
  55. SONG Y, Lin S, Chen J, Dang J, et al
    First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1043.
    PubMed     Abstract available


  56. WEI D, Niu B, Zhai B, Liu XB, et al
    Expression profiles and function prediction of tRNA-derived fragments in glioma.
    BMC Cancer. 2023;23:1015.
    PubMed     Abstract available


  57. YANG XS, Zhu P, Xie RX, Chen PF, et al
    Tracking tumor alteration in glioma through serum fibroblast activation protein combined with image.
    BMC Cancer. 2023;23:1012.
    PubMed     Abstract available


  58. ROZATI H, Chen J, Williams M
    Overall survival following stereotactic radiosurgery for ten or more brain metastases: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1004.
    PubMed     Abstract available


  59. WANG Z, Cui Y, Wang F, Xu L, et al
    DNA methylation-regulated LINC02587 inhibits ferroptosis and promotes the progression of glioma cells through the CoQ-FSP1 pathway.
    BMC Cancer. 2023;23:989.
    PubMed     Abstract available


  60. VINCENT CA, Nissen I, Dakhel S, Hornblad A, et al
    Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide.
    BMC Cancer. 2023;23:945.
    PubMed     Abstract available


  61. ROBINSON SD, Samuels M, Jones W, Gilbert D, et al
    Shooting the messenger: a systematic review investigating extracellular vesicle isolation and characterisation methods and their influence on understanding extracellular vesicles-radiotherapy interactions in glioblastoma.
    BMC Cancer. 2023;23:939.
    PubMed     Abstract available


  62. MING Y, Luo C, Ji B, Cheng J, et al
    ARPC5 acts as a potential prognostic biomarker that is associated with cell proliferation, migration and immune infiltrate in gliomas.
    BMC Cancer. 2023;23:937.
    PubMed     Abstract available


    September 2023
  63. CHENG WY, Shen CC, Liang YJ, Chiao MT, et al
    Polymorphism at codon 31 of CDKN1A (p21) as a predictive factor for bevacizumab therapy in glioblastoma multiforme.
    BMC Cancer. 2023;23:886.
    PubMed     Abstract available


  64. HATTORI EY, Arakawa Y, Mineharu Y, Furukawa K, et al
    Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy.
    BMC Cancer. 2023;23:849.
    PubMed     Abstract available


  65. SHAN E, Cao YN, Zhang Y, Chen W, et al
    Integrated profiling identifies CACNG3 as a prognostic biomarker for patients with glioma.
    BMC Cancer. 2023;23:846.
    PubMed     Abstract available


  66. LIU Z, Hong X, Wang L, Ma Z, et al
    Radiomic features from multiparametric magnetic resonance imaging predict molecular subgroups of pediatric low-grade gliomas.
    BMC Cancer. 2023;23:848.
    PubMed     Abstract available


    August 2023
  67. MIRANDA J, Vazquez-Blomquist D, Bringas R, Fernandez-de-Cossio J, et al
    A co-formulation of interferons alpha2b and gamma distinctively targets cell cycle in the glioblastoma-derived cell line U-87MG.
    BMC Cancer. 2023;23:806.
    PubMed     Abstract available


  68. TAN C, Wei J, Li Z, Tian N, et al
    Circ_0021350 plays an oncogene role by regulating miR-1207-3p/PIK3R3 in glioblastoma.
    BMC Cancer. 2023;23:808.
    PubMed     Abstract available


  69. WANG X, Chen J, Lei Z, Chen H, et al
    Propensity score-matched analysis comparing hippocampus-avoidance whole-brain radiotherapy plus simultaneous integrated boost with hippocampus‑avoidance whole-brain radiotherapy alone for multiple brain metastases-a retrospective study in multiple i
    BMC Cancer. 2023;23:796.
    PubMed     Abstract available


  70. NEUTEL CLG, Viozzi I, Overduin CG, Rijpma A, et al
    Study protocol for a multicenter randomised controlled trial on the (cost)effectiveness of biopsy combined with same-session MR-guided LITT versus biopsy alone in patients with primary irresectable glioblastoma (EMITT trial).
    BMC Cancer. 2023;23:788.
    PubMed     Abstract available


  71. SOUSA N, Geiss C, Bindila L, Lieberwirth I, et al
    Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion.
    BMC Cancer. 2023;23:762.
    PubMed     Abstract available


  72. ZHAO N, Weng S, Liu Z, Xu H, et al
    CRISPR-Cas9 identifies growth-related subtypes of glioblastoma with therapeutical significance through cell line knockdown.
    BMC Cancer. 2023;23:749.
    PubMed     Abstract available


  73. ZHONG K, Shi Y, Gao Y, Zhang H, et al
    First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.
    BMC Cancer. 2023;23:746.
    PubMed     Abstract available


  74. LI J, Guo Q, Xing R
    Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
    BMC Cancer. 2023;23:727.
    PubMed     Abstract available


    July 2023
  75. TAN Q, Wang Q, Jin S, Zhou F, et al
    Network Evolution Model-based prediction of tumor mutation burden from radiomic-clinical features in endometrial cancers.
    BMC Cancer. 2023;23:712.
    PubMed     Abstract available


  76. CHIEN CH, Lai CC, Chuang JY, Chu JM, et al
    Role of SH3GLB1 in the regulation of CD133 expression in GBM cells.
    BMC Cancer. 2023;23:713.
    PubMed     Abstract available


  77. WALTENBERGER M, Bernhardt D, Diehl C, Gempt J, et al
    Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiosurgery (SRS) to the resection cavity of brain metastases after surgical resection (SATURNUS): study protocol for a randomized phase III trial.
    BMC Cancer. 2023;23:709.
    PubMed     Abstract available


  78. TAO R, Huang R, Yang J, Wang J, et al
    Comprehensive analysis of the clinical and biological significances of cholesterol metabolism in lower-grade gliomas.
    BMC Cancer. 2023;23:692.
    PubMed     Abstract available


  79. YUEYANG M, Yaqin H, Guolian X, Wenjian Z, et al
    Glioma angiogenesis is boosted by ELK3 activating the HIF-1[Formula: see text]/VEGF-A signaling axis.
    BMC Cancer. 2023;23:662.
    PubMed     Abstract available


    June 2023
  80. PENG Y, Liu H, Wu Q, Wang L, et al
    Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma.
    BMC Cancer. 2023;23:596.
    PubMed     Abstract available


  81. XUE Z, Wang J, Wang Z, Liu J, et al
    SLC25A32 promotes malignant progression of glioblastoma by activating PI3K-AKT signaling pathway.
    BMC Cancer. 2023;23:589.
    PubMed     Abstract available


  82. SUN S, Yang C, Wang K, Huang R, et al
    Molecular and clinical characterization of PTRF in glioma via 1,022 samples.
    BMC Cancer. 2023;23:551.
    PubMed     Abstract available


  83. WEI L, Pan M, Jiang Q, Hu B, et al
    Eukaryotic initiation factor 4 A-3 promotes glioblastoma growth and invasion through the Notch1-dependent pathway.
    BMC Cancer. 2023;23:550.
    PubMed     Abstract available


  84. FU M, Zhou Z, Huang X, Chen Z, et al
    Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map.
    BMC Cancer. 2023;23:544.
    PubMed     Abstract available


  85. HAO Z, Huajun S, Zhen G, Yu X, et al
    AQP8 promotes glioma proliferation and growth, possibly through the ROS/PTEN/AKT signaling pathway.
    BMC Cancer. 2023;23:516.
    PubMed     Abstract available


  86. BABAZADEH SM, Zolfaghari MR, Zargar M, Baesi K, et al
    Interleukin-24-mediated antitumor effects against human glioblastoma via upregulation of P38 MAPK and endogenous TRAIL-induced apoptosis and LC3-II activation-dependent autophagy.
    BMC Cancer. 2023;23:519.
    PubMed     Abstract available


    May 2023
  87. AKANDA MR, Ahn EJ, Kim YJ, Salam SMA, et al
    Analysis of stromal PDGFR-beta and alpha-SMA expression and their clinical relevance in brain metastases of breast cancer patients.
    BMC Cancer. 2023;23:468.
    PubMed     Abstract available


  88. CHEN Y, Ma F, Zhang Z, Guo Y, et al
    LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.
    BMC Cancer. 2023;23:455.
    PubMed     Abstract available


  89. DUAN X, Yang B, Zhao C, Tie B, et al
    Prognostic value of preoperative hematological markers in patients with glioblastoma multiforme and construction of random survival forest model.
    BMC Cancer. 2023;23:432.
    PubMed     Abstract available


  90. LIU ZY, Lan T, Tang F, He YZ, et al
    ZDHHC15 promotes glioma malignancy and acts as a novel prognostic biomarker for patients with glioma.
    BMC Cancer. 2023;23:420.
    PubMed     Abstract available


  91. WANG X, Zhang H, Zhang M, Zhang X, et al
    Proteogenomic characterization of ferroptosis regulators reveals therapeutic potential in glioblastoma.
    BMC Cancer. 2023;23:415.
    PubMed     Abstract available


  92. ZOU R, Zhong X, Liang K, Zhi C, et al
    Elevated LILRB1 expression predicts poor prognosis and is associated with tumor immune infiltration in patients with glioma.
    BMC Cancer. 2023;23:403.
    PubMed     Abstract available


    April 2023
  93. THIVAT E, Casile M, Moreau J, Molnar I, et al
    Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol).
    BMC Cancer. 2023;23:344.
    PubMed     Abstract available


  94. ZHOU T, Zhu S, Xiong Q, Gan J, et al
    Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2023;23:333.
    PubMed     Abstract available


  95. KELLER KM, Koetsier J, Schild L, Amo-Addae V, et al
    The potential of PARP as a therapeutic target across pediatric solid malignancies.
    BMC Cancer. 2023;23:310.
    PubMed     Abstract available


    March 2023
  96. WANG H, Xing R, Li M, Zhang M, et al
    Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study.
    BMC Cancer. 2023;23:289.
    PubMed     Abstract available


  97. CROUZEN JA, Petoukhova AL, Broekman MLD, Fiocco M, et al
    SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases.
    BMC Cancer. 2023;23:273.
    PubMed     Abstract available


  98. KING AL, Acquaye-Mallory AA, Vera E, Mendoza T, et al
    Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trial.
    BMC Cancer. 2023;23:262.
    PubMed     Abstract available


  99. LIU X, Li Z, Sun J, Zhang Z, et al
    Interaction between PD-L1 and soluble VEGFR1 in glioblastoma-educated macrophages.
    BMC Cancer. 2023;23:259.
    PubMed     Abstract available


  100. ZHANG M, Liu X, Wang D, Ruan X, et al
    A novel cuproptosis-related gene signature to predict prognosis in Glioma.
    BMC Cancer. 2023;23:237.
    PubMed     Abstract available


  101. CAIN SA, Pope B, Mangiola S, Mantamadiotis T, et al
    Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression.
    BMC Cancer. 2023;23:216.
    PubMed     Abstract available


  102. XU Z, Hao X, Wang Q, Yang K, et al
    Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.
    BMC Cancer. 2023;23:206.
    PubMed     Abstract available


  103. GEURTS BS, Battaglia TW, van Berge Henegouwen JM, Zeverijn LJ, et al
    Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
    BMC Cancer. 2023;23:205.
    PubMed     Abstract available


    February 2023
  104. MADDISON K, Bowden NA, Graves MC, Tooney PA, et al
    Characteristics of vasculogenic mimicry and tumour to endothelial transdifferentiation in human glioblastoma: a systematic review.
    BMC Cancer. 2023;23:185.
    PubMed     Abstract available


  105. QUESNEL A, Coles N, Angione C, Dey P, et al
    Glycosylation spectral signatures for glioma grade discrimination using Raman spectroscopy.
    BMC Cancer. 2023;23:174.
    PubMed     Abstract available


  106. ZHU H, Tan J, Pan X, Ouyang H, et al
    HELLPAR/RRM2 axis related to HMMR as novel prognostic biomarker in gliomas.
    BMC Cancer. 2023;23:125.
    PubMed     Abstract available


  107. ZHU X, Chen D, Sun Y, Yang S, et al
    LncRNA WEE2-AS1 is a diagnostic biomarker that predicts poor prognoses in patients with glioma.
    BMC Cancer. 2023;23:120.
    PubMed     Abstract available


    January 2023
  108. DAI L, Guo X, Xing Z, Tao Y, et al
    Multi-omics analyses of CD276 in pan-cancer reveals its clinical prognostic value in glioblastoma and other major cancer types.
    BMC Cancer. 2023;23:102.
    PubMed     Abstract available


  109. ZHANG GT, Liu Q, Zuo FX, Liu HJ, et al
    Clinical and genomic features in patients with second primary glioblastoma following first primary renal cell carcinoma.
    BMC Cancer. 2023;23:104.
    PubMed     Abstract available


  110. LILJEDAHL E, Konradsson E, Gustafsson E, Jonsson KF, et al
    Combined anti-C1-INH and radiotherapy against glioblastoma.
    BMC Cancer. 2023;23:106.
    PubMed     Abstract available


  111. LIEDE A, Sebby W, Miriyala AKR, Potluri R, et al
    Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States.
    BMC Cancer. 2023;23:78.
    PubMed     Abstract available


  112. LI L, Zhang C, Wang Z, Wang Y, et al
    Development of an integrated predictive model for postoperative glioma-related epilepsy using gene-signature and clinical data.
    BMC Cancer. 2023;23:42.
    PubMed     Abstract available


  113. WANG X, Li X, Wu Y, Hong J, et al
    The prognostic significance of tumor-associated neutrophils and circulating neutrophils in glioblastoma (WHO CNS5 classification).
    BMC Cancer. 2023;23:20.
    PubMed     Abstract available


  114. LI C, Xi S, Chen Y, Guo C, et al
    Clinical significance of histopathological features of paired recurrent gliomas: a cohort study from a single cancer center.
    BMC Cancer. 2023;23:8.
    PubMed     Abstract available


    December 2022
  115. DAS S, Faruqi S, Nordal R, Starreveld Y, et al
    A phase III, multicenter, randomized controlled trial of preoperative versus postoperative stereotactic radiosurgery for patients with surgically resectable brain metastases.
    BMC Cancer. 2022;22:1368.
    PubMed     Abstract available


  116. ZHU Y, Teng Y, Xu S, Xu Y, et al
    Eczema as a protective factor for brain cancer: a meta-analysis.
    BMC Cancer. 2022;22:1360.
    PubMed     Abstract available


  117. PENG D, Liang P, Zhong C, Xu P, et al
    Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non-small-cell lung cancer patients: a prospective observational study.
    BMC Cancer. 2022;22:1323.
    PubMed     Abstract available


  118. ZWAIG M, Baguette A, Hu B, Johnston M, et al
    Detection and genomic analysis of BRAF fusions in Juvenile Pilocytic Astrocytoma through the combination and integration of multi-omic data.
    BMC Cancer. 2022;22:1297.
    PubMed     Abstract available


  119. SHANG K, Huang H, Xu Y, Liu Y, et al
    Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation.
    BMC Cancer. 2022;22:1295.
    PubMed     Abstract available


  120. ZHAO S, Ji W, Shen Y, Fan Y, et al
    Expression of hub genes of endothelial cells in glioblastoma-A prognostic model for GBM patients integrating single-cell RNA sequencing and bulk RNA sequencing.
    BMC Cancer. 2022;22:1274.
    PubMed     Abstract available


  121. TOMITA N, Ishiyama H, Makita C, Ohshima Y, et al
    Daily irradiation versus irradiation at two- to three-day intervals in stereotactic radiotherapy for patients with 1-5 brain metastases: study protocol for a multicenter open-label randomized phase II trial.
    BMC Cancer. 2022;22:1259.
    PubMed     Abstract available


    November 2022
  122. KIM JW, Park SH, Choi SA, Kim SK, et al
    Molecular subgrouping of medulloblastoma in pediatric population using the NanoString assay and comparison with immunohistochemistry methods.
    BMC Cancer. 2022;22:1221.
    PubMed     Abstract available


  123. LIU X, Yang J, Li H, Wang Q, et al
    Quantifying substantial carcinogenesis of genetic and environmental factors from measurement error in the number of stem cell divisions.
    BMC Cancer. 2022;22:1194.
    PubMed     Abstract available


  124. ZHANG Y, Wang X, Shi M, Song Y, et al
    Programmed death ligand 1 and tumor-infiltrating CD8(+) T lymphocytes are associated with the clinical features in meningioma.
    BMC Cancer. 2022;22:1171.
    PubMed     Abstract available


    October 2022
  125. GALLITTO M, Savacool M, Lee A, Wang TJC, et al
    Feasibility of fractionated gamma knife radiosurgery in the management of newly diagnosed Glioblastoma.
    BMC Cancer. 2022;22:1095.
    PubMed     Abstract available


    September 2022
  126. CHEN Z, Zhou L, Zhao M, Cao K, et al
    Real-world analysis of different intracranial radiation therapies in non-small cell lung cancer patients with 1-4 brain metastases.
    BMC Cancer. 2022;22:1010.
    PubMed     Abstract available


  127. CHOI JM, Lim SH, Liu ZP, Lee TK, et al
    Flagellin synergistically enhances anti-tumor effect of EGFRvIII peptide in a glioblastoma-bearing mouse brain tumor model.
    BMC Cancer. 2022;22:986.
    PubMed     Abstract available


  128. TU Z, Ji Q, Han Q, Long X, et al
    Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
    BMC Cancer. 2022;22:973.
    PubMed     Abstract available


  129. WENDLER J, Fox CP, Valk E, Steinheber C, et al
    Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.
    BMC Cancer. 2022;22:971.
    PubMed     Abstract available


    August 2022
  130. HUANG Y, Ouyang F, Yang F, Zhang N, et al
    The expression of Hexokinase 2 and its hub genes are correlated with the prognosis in glioma.
    BMC Cancer. 2022;22:900.
    PubMed     Abstract available


  131. YU H, Gong M, Qi J, Zhao C, et al
    Systematic transcriptome profiling of pyroptosis related signature for predicting prognosis and immune landscape in lower grade glioma.
    BMC Cancer. 2022;22:885.
    PubMed     Abstract available


  132. JIANG L, Yang J, Xu Q, Lv K, et al
    Machine learning for the micropeptide encoded by LINC02381 regulates ferroptosis through the glucose transporter SLC2A10 in glioblastoma.
    BMC Cancer. 2022;22:882.
    PubMed     Abstract available


  133. SCHULZ JA, Rodgers LT, Kryscio RJ, Hartz AMS, et al
    Characterization and comparison of human glioblastoma models.
    BMC Cancer. 2022;22:844.
    PubMed     Abstract available


  134. ROY C, Avril S, Legendre C, Lelievre B, et al
    A role for ceruloplasmin in the control of human glioblastoma cell responses to radiation.
    BMC Cancer. 2022;22:843.
    PubMed     Abstract available


    July 2022
  135. GUAN Y, Pan M, Yang J, Lu Q, et al
    A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol.
    BMC Cancer. 2022;22:827.
    PubMed     Abstract available


  136. YU J, Gao G, Wei X, Wang Y, et al
    TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
    BMC Cancer. 2022;22:786.
    PubMed     Abstract available


  137. ABUHAMED J, Nikkila A, Raitanen J, Alimam W, et al
    Incidence trends of childhood central nervous system tumors in Finland 1990-2017.
    BMC Cancer. 2022;22:784.
    PubMed     Abstract available


  138. WU X, Li C, Wang Z, Zhang Y, et al
    A bioinformatic analysis study of m(7)G regulator-mediated methylation modification patterns and tumor microenvironment infiltration in glioblastoma.
    BMC Cancer. 2022;22:729.
    PubMed     Abstract available


    June 2022
  139. LI JD, Farah AA, Huang ZG, Zhai GQ, et al
    Clinical significance and potential regulatory mechanism of overexpression of pituitary tumor-transforming gene transcription factor in bladder cancer.
    BMC Cancer. 2022;22:713.
    PubMed     Abstract available


  140. WANG J, Qiu X, Huang J, Zhuo Z, et al
    Development and validation of a novel mitophagy-related gene prognostic signature for glioblastoma multiforme.
    BMC Cancer. 2022;22:644.
    PubMed     Abstract available


  141. WICK A, Sander A, Koch M, Bendszus M, et al
    Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
    BMC Cancer. 2022;22:645.
    PubMed     Abstract available


  142. MALA U, Baral TK, Somasundaram K
    Integrative analysis of cell adhesion molecules in glioblastoma identified prostaglandin F2 receptor inhibitor (PTGFRN) as an essential gene.
    BMC Cancer. 2022;22:642.
    PubMed     Abstract available


  143. DING MR, Qu YJ, Peng X, Chen JF, et al
    Pyroptosis-related prognosis model, immunocyte infiltration characterization, and competing endogenous RNA network of glioblastoma.
    BMC Cancer. 2022;22:611.
    PubMed     Abstract available


  144. GATELY L, Drummond K, Rosenthal M, Harrup R, et al
    Beyond standard data collection - the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry).
    BMC Cancer. 2022;22:604.
    PubMed     Abstract available


    May 2022
  145. YANG H, Wen L, Pan Y, Shan C, et al
    Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
    BMC Cancer. 2022;22:580.
    PubMed     Abstract available


  146. XU X, Yuan H, Pan J, Chen W, et al
    The identification of miRNA and mRNA expression profiles associated with pediatric atypical teratoid/rhabdoid tumor.
    BMC Cancer. 2022;22:499.
    PubMed     Abstract available


  147. FISCHER GF, Brugge D, Andratschke N, Baumert BG, et al
    Postoperative radiotherapy for meningiomas - a decision-making analysis.
    BMC Cancer. 2022;22:492.
    PubMed     Abstract available


    April 2022
  148. KOOPAIE M, Ghafourian M, Manifar S, Younespour S, et al
    Evaluation of CSTB and DMBT1 expression in saliva of gastric cancer patients and controls.
    BMC Cancer. 2022;22:473.
    PubMed     Abstract available


  149. LI J, Wang J, Ding Y, Zhao J, et al
    Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas.
    BMC Cancer. 2022;22:466.
    PubMed     Abstract available


  150. ZHANG J, Guo Z, Xie Q, Zhong C, et al
    Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-kappaB signaling pathway.
    BMC Cancer. 2022;22:457.
    PubMed     Abstract available


  151. KLEINBERGER I, Sanders E, Staes K, Van Troys M, et al
    Innovative mouse models for the tumor suppressor activity of Protocadherin-10 isoforms.
    BMC Cancer. 2022;22:451.
    PubMed     Abstract available


  152. ARUNACHALAM E, Rogers W, Simpson GR, Moller-Levet C, et al
    HOX and PBX gene dysregulation as a therapeutic target in glioblastoma multiforme.
    BMC Cancer. 2022;22:400.
    PubMed     Abstract available


  153. WANG C, Liu C, Chen J, Jiang H, et al
    Effect of neoadjuvant iodine-125 brachytherapy upon resection of glioma.
    BMC Cancer. 2022;22:397.
    PubMed     Abstract available


  154. BELANGER K, Ung TH, Damek D, Lillehei KO, et al
    Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.
    BMC Cancer. 2022;22:367.
    PubMed     Abstract available


    March 2022
  155. RYDEN I, Thurin E, Carstam L, Smits A, et al
    Correction: Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study.
    BMC Cancer. 2022;22:350.
    PubMed    


  156. SANDER C, Frydrychowicz C, Prasse G, Taubenheim S, et al
    The impact of neurological performance and volumetrics on overall survival in brain metastasis in colorectal cancer: a retrospective single-center case series.
    BMC Cancer. 2022;22:336.
    PubMed     Abstract available


  157. HESSLER N, Junger ST, Meissner AK, Kocher M, et al
    Recurrent brain metastases: the role of resection of in a comprehensive multidisciplinary treatment setting.
    BMC Cancer. 2022;22:275.
    PubMed     Abstract available


  158. EGGEN AC, Hospers GAP, Bosma I, Kramer MCA, et al
    Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases.
    BMC Cancer. 2022;22:247.
    PubMed     Abstract available


  159. BI Y, Wu ZH, Cao F
    Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma.
    BMC Cancer. 2022;22:233.
    PubMed     Abstract available


  160. PUHAKKA I, Kuitunen H, Jakala P, Sonkajarvi E, et al
    Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis.
    BMC Cancer. 2022;22:236.
    PubMed     Abstract available


  161. LI C, Liu F, Sun L, Liu Z, et al
    Natural killer cell-related gene signature predicts malignancy of glioma and the survival of patients.
    BMC Cancer. 2022;22:230.
    PubMed     Abstract available


    February 2022
  162. MOU Y, Zhang L, Liu Z, Song X, et al
    Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma.
    BMC Cancer. 2022;22:215.
    PubMed     Abstract available


  163. WANG X, Wang Y, Xie F, Song ZT, et al
    Norepinephrine promotes glioma cell migration through up-regulating the expression of Twist1.
    BMC Cancer. 2022;22:213.
    PubMed     Abstract available


  164. FU J, Zeng J, Huang M, Liang S, et al
    Primary versus postoperative gamma knife radiosurgery for intracranial benign meningiomas: a matched cohort retrospective study.
    BMC Cancer. 2022;22:206.
    PubMed     Abstract available


  165. ZENG Y, Guo T, Zhou Y, Zhao Y, et al
    Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.
    BMC Cancer. 2022;22:198.
    PubMed     Abstract available


  166. ZHANG X, Wu Y, Sun X, Cui Q, et al
    The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
    BMC Cancer. 2022;22:190.
    PubMed     Abstract available


  167. BUENO-MARTINEZ E, Lara-Almunia M, Rodriguez-Arias C, Otero-Rodriguez A, et al
    Polymorphisms in autophagy genes are genetic susceptibility factors in glioblastoma development.
    BMC Cancer. 2022;22:146.
    PubMed     Abstract available


  168. TRIPATHI PH, Akhtar J, Arora J, Saran RK, et al
    Quantitative proteomic analysis of GnRH agonist treated GBM cell line LN229 revealed regulatory proteins inhibiting cancer cell proliferation.
    BMC Cancer. 2022;22:133.
    PubMed     Abstract available


    January 2022
  169. WEI R, Zhao C, Li J, Yang F, et al
    Online calculator to predict early mortality in patient with surgically treated recurrent lower-grade glioma.
    BMC Cancer. 2022;22:114.
    PubMed     Abstract available


  170. MAO XG, Xue XY, Wang L, Lin W, et al
    Deep learning identified glioblastoma subtypes based on internal genomic expression ranks.
    BMC Cancer. 2022;22:86.
    PubMed     Abstract available


  171. REN J, Zhang X, Cao J, Tian J, et al
    Radiosynthesis of a novel antisense imaging probe targeting LncRNA HOTAIR in malignant glioma.
    BMC Cancer. 2022;22:79.
    PubMed     Abstract available


  172. SCHAFF LR, Lobbous M, Carlow D, Schofield R, et al
    Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study.
    BMC Cancer. 2022;22:60.
    PubMed     Abstract available


  173. HOSEINI B, Rahmatinejad Z, Goshayeshi L, Bergquist R, et al
    Colorectal Cancer in North-Eastern Iran: a retrospective, comparative study of early-onset and late-onset cases based on data from the Iranian hereditary colorectal cancer registry.
    BMC Cancer. 2022;22:48.
    PubMed     Abstract available


  174. ALVAREZ-TORRES MDM, Fuster-Garcia E, Juan-Albarracin J, Reynes G, et al
    Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification.
    BMC Cancer. 2022;22:40.
    PubMed     Abstract available


    December 2021
  175. RAYMOND P, Klein M, Cuny T, Klein O, et al
    High prevalence of anterior pituitary deficiencies after cranial radiation therapy for skull base meningiomas.
    BMC Cancer. 2021;21:1346.
    PubMed     Abstract available


  176. ZHANG M, Cheng Y, Xue Z, Sun Q, et al
    A novel pyroptosis-related gene signature predicts the prognosis of glioma through immune infiltration.
    BMC Cancer. 2021;21:1311.
    PubMed     Abstract available


    November 2021
  177. MACHARIA LW, Muriithi W, Heming CP, Nyaga DK, et al
    The genotypic and phenotypic impact of hypoxia microenvironment on glioblastoma cell lines.
    BMC Cancer. 2021;21:1248.
    PubMed     Abstract available


  178. POON MTC, Bruce M, Simpson JE, Hannan CJ, et al
    Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies.
    BMC Cancer. 2021;21:1240.
    PubMed     Abstract available


  179. WEN J, Rusch M, Brady SW, Shao Y, et al
    The landscape of coding RNA editing events in pediatric cancer.
    BMC Cancer. 2021;21:1233.
    PubMed     Abstract available


  180. XIE H, Yuan C, Ding XH, Li JJ, et al
    Identification of key genes and pathways associated with resting mast cells in meningioma.
    BMC Cancer. 2021;21:1209.
    PubMed     Abstract available


  181. DJUZENOVA CS, Fischer T, Katzer A, Sisario D, et al
    Opposite effects of the triple target (DNA-PK/PI3K/mTOR) inhibitor PI-103 on the radiation sensitivity of glioblastoma cell lines proficient and deficient in DNA-PKcs.
    BMC Cancer. 2021;21:1201.
    PubMed     Abstract available


  182. SU X, Yang Y, Yang Q, Pang B, et al
    NOX4-derived ROS-induced overexpression of FOXM1 regulates aerobic glycolysis in glioblastoma.
    BMC Cancer. 2021;21:1181.
    PubMed     Abstract available


  183. XIE Y, Gong C, Zhang J, Wang L, et al
    Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
    BMC Cancer. 2021;21:1174.
    PubMed     Abstract available


    October 2021
  184. TONNEAU M, Mouttet-Audouard R, Le Tinier F, Mirabel X, et al
    Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review.
    BMC Cancer. 2021;21:1168.
    PubMed     Abstract available


  185. ARAKAWA Y, Sasaki K, Mineharu Y, Uto M, et al
    A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).
    BMC Cancer. 2021;21:1105.
    PubMed     Abstract available


  186. KEMMERER CL, Schittenhelm J, Dubois E, Neumann L, et al
    Cerebrospinal fluid cytokine levels are associated with macrophage infiltration into tumor tissues of glioma patients.
    BMC Cancer. 2021;21:1108.
    PubMed     Abstract available


  187. LIU R, Dai W, Wu A, Li Y, et al
    CircCDC45 promotes the malignant progression of glioblastoma by modulating the miR-485-5p/CSF-1 axis.
    BMC Cancer. 2021;21:1090.
    PubMed     Abstract available


    September 2021
  188. CHENG S, Yang L, Dai X, Wang J, et al
    The risk and prognostic factors for brain metastases in esophageal cancer patients: an analysis of the SEER database.
    BMC Cancer. 2021;21:1057.
    PubMed     Abstract available


  189. MAKINO Y, Arakawa Y, Yoshioka E, Shofuda T, et al
    Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
    BMC Cancer. 2021;21:1025.
    PubMed     Abstract available


  190. TYLDESLEY-MARSHALL N, Greenfield S, Neilson SJ, English M, et al
    The role of Magnetic Resonance Images (MRIs) in coping for patients with brain tumours and their parents: a qualitative study.
    BMC Cancer. 2021;21:1013.
    PubMed     Abstract available


  191. MIKIC N, Poulsen FR, Kristoffersen KB, Laursen RJ, et al
    Study protocol for OptimalTTF-2: enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial.
    BMC Cancer. 2021;21:1010.
    PubMed     Abstract available


    August 2021
  192. HACKSHAW MD, Danysh HE, Henderson M, Wang E, et al
    Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review.
    BMC Cancer. 2021;21:967.
    PubMed     Abstract available


  193. LI Y, Guo D
    Genome-wide profiling of alternative splicing in glioblastoma and their clinical value.
    BMC Cancer. 2021;21:958.
    PubMed     Abstract available


  194. KIM YJ, Oh H, Lee SJ, Kim KM, et al
    Prognostic significance of the postoperative prognostic nutritional index in patients with glioblastoma: a retrospective study.
    BMC Cancer. 2021;21:942.
    PubMed     Abstract available


  195. XIAO J, Xu L, Ding Y, Wang W, et al
    Does post-operative radiotherapy improve the treatment outcomes of intracranial hemangiopericytoma? A retrospective study.
    BMC Cancer. 2021;21:915.
    PubMed     Abstract available


    July 2021
  196. WANG X, Cai J, Zeng Z, Liu A, et al
    Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
    BMC Cancer. 2021;21:873.
    PubMed     Abstract available


  197. GINZAC A, Dupic G, Brun L, Molnar I, et al
    Preoperative stereotactic radiosurgery for brain metastases: the STEP study protocol for a multicentre, prospective, phase-II trial.
    BMC Cancer. 2021;21:864.
    PubMed     Abstract available


  198. ASANO K, Fumoto T, Matsuzaka M, Hasegawa S, et al
    Combination chemoradiotherapy with temozolomide, vincristine, and interferon-beta might improve outcomes regardless of O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation status in newly glioblastoma.
    BMC Cancer. 2021;21:867.
    PubMed     Abstract available


  199. SYAFRUDDIN SE, Nazarie WFWM, Moidu NA, Soon BH, et al
    Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
    BMC Cancer. 2021;21:850.
    PubMed     Abstract available


  200. HUANG T, Chen Y, Zeng Y, Xu C, et al
    Long non-coding RNA PSMA3-AS1 promotes glioma progression through modulating the miR-411-3p/HOXA10 pathway.
    BMC Cancer. 2021;21:844.
    PubMed     Abstract available


  201. ZHANG F, He Q, Luo G, Long Y, et al
    The combination of (13)N-ammonia and (11)C-methionine in differentiation of residual/recurrent pituitary adenoma from the pituitary gland remnant after trans-sphenoidal Adenomectomy.
    BMC Cancer. 2021;21:837.
    PubMed     Abstract available


  202. SHEN H, Deng G, Chen Q, Qian J, et al
    The incidence, risk factors and predictive nomograms for early death of lung cancer with synchronous brain metastasis: a retrospective study in the SEER database.
    BMC Cancer. 2021;21:825.
    PubMed     Abstract available


    June 2021
  203. SCHEICHEL F, Marhold F, Pinggera D, Kiesel B, et al
    Influence of preoperative corticosteroid treatment on rate of diagnostic surgeries in primary central nervous system lymphoma: a multicenter retrospective study.
    BMC Cancer. 2021;21:754.
    PubMed     Abstract available


  204. LU J, Peng Y, Huang R, Feng Z, et al
    Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    BMC Cancer. 2021;21:723.
    PubMed     Abstract available


  205. TU Z, Xiong H, Qiu Y, Li G, et al
    Limited recurrence distance of glioblastoma under modern radiotherapy era.
    BMC Cancer. 2021;21:720.
    PubMed     Abstract available


  206. ZHU W, Zhao H, Xu F, Huang B, et al
    The lipid-lowering drug fenofibrate combined with si-HOTAIR can effectively inhibit the proliferation of gliomas.
    BMC Cancer. 2021;21:664.
    PubMed     Abstract available


  207. MOON HH, Kim HS, Park JE, Kim YH, et al
    Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
    BMC Cancer. 2021;21:654.
    PubMed     Abstract available


    May 2021
  208. SHAN Q, Shi J, Wang X, Guo J, et al
    A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study.
    BMC Cancer. 2021;21:640.
    PubMed     Abstract available


  209. ZHU J, Wang H, Sun Q, Ji X, et al
    Correction to: Nrf2 is required to maintain the self-renewal of glioma stem cells.
    BMC Cancer. 2021;21:582.
    PubMed    


  210. MILLS MN, Naz A, Thawani C, Walker C, et al
    Capecitabine and stereotactic radiation in the management of breast cancer brain metastases.
    BMC Cancer. 2021;21:552.
    PubMed     Abstract available


  211. MAJCHRZAK-CELINSKA A, Misiorek JO, Kruhlenia N, Przybyl L, et al
    COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/beta-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
    BMC Cancer. 2021;21:493.
    PubMed     Abstract available


    April 2021
  212. YAMAMURA J, Kamigaki S, Fujita J, Osato H, et al
    New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
    BMC Cancer. 2021;21:476.
    PubMed     Abstract available


  213. XU B, Huo Z, Huang H, Ji W, et al
    The expression and prognostic value of the epidermal growth factor receptor family in glioma.
    BMC Cancer. 2021;21:451.
    PubMed     Abstract available


  214. AMIN S, Baine M, Meza J, Lin C, et al
    The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type.
    BMC Cancer. 2021;21:387.
    PubMed     Abstract available


  215. RADES D, Witteler J, Olbrich D, Trillenberg P, et al
    A prospective interventional study evaluating seizure activity during a radiotherapy course for high-grade gliomas (SURF-ROGG).
    BMC Cancer. 2021;21:386.
    PubMed     Abstract available


    March 2021
  216. KUO CS, Tung PH, Huang AC, Wang CC, et al
    A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    BMC Cancer. 2021;21:309.
    PubMed     Abstract available


  217. XI J, Hassan B, Katumba RGN, Khaddour K, et al
    The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
    BMC Cancer. 2021;21:285.
    PubMed     Abstract available


  218. KIANG KM, Chan AA, Leung GK
    Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
    BMC Cancer. 2021;21:265.
    PubMed     Abstract available


  219. ZHANG C, Liu H, Xu P, Tan Y, et al
    Identification and validation of a five-lncRNA prognostic signature related to Glioma using bioinformatics analysis.
    BMC Cancer. 2021;21:251.
    PubMed     Abstract available


  220. RYDEN I, Thurin E, Carstam L, Smits A, et al
    Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study.
    BMC Cancer. 2021;21:248.
    PubMed     Abstract available


  221. MILLS MN, Walker C, Thawani C, Naz A, et al
    Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
    BMC Cancer. 2021;21:223.
    PubMed     Abstract available


  222. MASALHA W, Daka K, Woerner J, Pompe N, et al
    Metabolic alterations in meningioma reflect the clinical course.
    BMC Cancer. 2021;21:211.
    PubMed     Abstract available


    February 2021
  223. ZHANG Y, Zou D, Yin J, Zhang L, et al
    Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
    BMC Cancer. 2021;21:183.
    PubMed     Abstract available


  224. KHAN M, Zhao Z, Arooj S, Liao G, et al
    Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis.
    BMC Cancer. 2021;21:167.
    PubMed     Abstract available


  225. KEOGH RJ, Aslam R, Hennessy MA, Coyne Z, et al
    One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
    BMC Cancer. 2021;21:140.
    PubMed     Abstract available


  226. GUAN Y, Xiong J, Pan M, Shi W, et al
    Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience.
    BMC Cancer. 2021;21:123.
    PubMed     Abstract available


    January 2021
  227. LIU G, Liu D, Huang J, Li J, et al
    Comprehensive analysis of ceRNA network related to lincRNA in glioblastoma and prediction of clinical prognosis.
    BMC Cancer. 2021;21:98.
    PubMed     Abstract available


  228. LIU FM, Gao YF, Kong Y, Guan Y, et al
    The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.
    BMC Cancer. 2021;21:83.
    PubMed     Abstract available


  229. WEN J, Chen W, Zhu Y, Zhang P, et al
    Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.
    BMC Cancer. 2021;21:81.
    PubMed     Abstract available


  230. CHEN B, Chen C, Zhang Y, Xu J, et al
    Recent incidence trend of elderly patients with glioblastoma in the United States, 2000-2017.
    BMC Cancer. 2021;21:54.
    PubMed     Abstract available


  231. WANG Y, Zhang Y, Hong Y, Zeng P, et al
    Advance directives and end-of-life care: knowledge and preferences of patients with brain Tumours from Anhui, China.
    BMC Cancer. 2021;21:25.
    PubMed     Abstract available


    December 2020
  232. HIGGINS DMO, Caliva M, Schroeder M, Carlson B, et al
    Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas.
    BMC Cancer. 2020;20:1213.
    PubMed     Abstract available


  233. COLLINS DC, Sundar R, Constantinidou A, Dolling D, et al
    Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
    BMC Cancer. 2020;20:1210.
    PubMed     Abstract available


    November 2020
  234. YU X, Wang Y, Yuan Z, Yu H, et al
    Benefit of dosimetry distribution for patients with multiple brain metastases from non-small cell lung cancer by a Cyberknife stereotactic radiosurgery (SRS) system.
    BMC Cancer. 2020;20:1144.
    PubMed     Abstract available


  235. LI X, Meng Y
    Analyses of metastasis-associated genes in IDH wild-type glioma.
    BMC Cancer. 2020;20:1114.
    PubMed     Abstract available


  236. ZHU Z, Lan Y, Wang L, Ge J, et al
    A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    BMC Cancer. 2020;20:1072.
    PubMed     Abstract available


  237. AFTAHY AK, Barz M, Krauss P, Liesche F, et al
    Intraventricular neuroepithelial tumors: surgical outcome, technical considerations and review of literature.
    BMC Cancer. 2020;20:1060.
    PubMed     Abstract available


    October 2020
  238. CHIA BSH, Leong JY, Ong ALK, Lim C, et al
    Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol.
    BMC Cancer. 2020;20:1045.
    PubMed     Abstract available


  239. DING X, Yang L, Geng X, Zou Y, et al
    CircRNAs as potential biomarkers for the clinicopathology and prognosis of glioma patients: a meta-analysis.
    BMC Cancer. 2020;20:1005.
    PubMed     Abstract available


  240. GUENOLE M, Lucia F, Bourbonne V, Dissaux G, et al
    Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases.
    BMC Cancer. 2020;20:991.
    PubMed     Abstract available


  241. FENG J, Ouyang Y, Xu D, He Q, et al
    Genetic variants in MIR17HG affect the susceptibility and prognosis of glioma in a Chinese Han population.
    BMC Cancer. 2020;20:976.
    PubMed     Abstract available


  242. HONG KT, Lee DH, Kim BK, An HY, et al
    Treatment outcome and long-term follow-up of central nervous system germ cell tumor using upfront chemotherapy with subsequent photon or proton radiation therapy: a single tertiary center experience of 127 patients.
    BMC Cancer. 2020;20:979.
    PubMed     Abstract available


  243. BLECKMANN A, Kirchner B, Nietert M, Peeck M, et al
    Impact of pre-OP independence in patients with limited brain metastases on long-term survival.
    BMC Cancer. 2020;20:973.
    PubMed     Abstract available


    September 2020
  244. WANG J, Tong L, Lin G, Wang H, et al
    Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients.
    BMC Cancer. 2020;20:931.
    PubMed     Abstract available


  245. DU F, Hou Q
    SNHG17 drives malignant behaviors in astrocytoma by targeting miR-876-5p/ERLIN2 axis.
    BMC Cancer. 2020;20:839.
    PubMed     Abstract available


    August 2020
  246. COSTE A, Bailey HD, Kartal-Kaess M, Renella R, et al
    Parental occupational exposure to pesticides and risk of childhood cancer in Switzerland: a census-based cohort study.
    BMC Cancer. 2020;20:819.
    PubMed     Abstract available


  247. HEILAND DH, Ohle R, Cipriani D, Franco P, et al
    Characterization of longitudinal transformation of T2-hyperintensity in oligodendroglioma.
    BMC Cancer. 2020;20:818.
    PubMed     Abstract available


    July 2020
  248. LOCSEI Z, Farkas R, Borbasne Farkas K, Sebestyen K, et al
    Assessment of the results and hematological side effects of 3D conformal and IMRT/ARC therapies delivered during craniospinal irradiation of childhood tumors with a follow-up period of five years.
    BMC Cancer. 2020;20:702.
    PubMed     Abstract available


  249. ZHAO Y, He JY, Cui JZ, Meng ZQ, et al
    Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing.
    BMC Cancer. 2020;20:690.
    PubMed     Abstract available


  250. LIN J, Yu L, Fu Y, Chen H, et al
    A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report.
    BMC Cancer. 2020;20:630.
    PubMed     Abstract available


  251. MEZEI T, Hajdu M, Czigleczki G, Lotz G, et al
    Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review.
    BMC Cancer. 2020;20:615.
    PubMed     Abstract available


    June 2020
  252. MEHTA P, Janssen S, Fahlbusch FB, Schmid SM, et al
    Sparing the hippocampus and the hypothalamic- pituitary region during whole brain radiotherapy: a volumetric modulated arc therapy planning study.
    BMC Cancer. 2020;20:610.
    PubMed     Abstract available


  253. XU T, Zhang X, Zhang S, Liu C, et al
    Imaging features and prognostic value of (18)F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study.
    BMC Cancer. 2020;20:596.
    PubMed     Abstract available


  254. GROSU AL, Frings L, Bentsalo I, Oehlke O, et al
    Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) - a phase II prospective randomized multicenter trial (NOA-14, ARO 2015-3, DKTK-ROG).
    BMC Cancer. 2020;20:532.
    PubMed     Abstract available


  255. DEVECKA M, Duma MN, Wilkens JJ, Kampfer S, et al
    Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting.
    BMC Cancer. 2020;20:501.
    PubMed     Abstract available


    May 2020
  256. BUCKSCH K, Zachariae S, Aretz S, Buttner R, et al
    Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study.
    BMC Cancer. 2020;20:460.
    PubMed     Abstract available


  257. WAKUDA K, Yamaguchi H, Kenmotsu H, Fukuda M, et al
    A phase II study of Osimertinib for patients with radiotherapy-naive CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
    BMC Cancer. 2020;20:370.
    PubMed     Abstract available


    April 2020
  258. FURUSE M, Kuwabara H, Ikeda N, Hattori Y, et al
    PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
    BMC Cancer. 2020;20:277.
    PubMed     Abstract available


    March 2020
  259. NAWROCKI S, Sugajska A
    Study protocol: watchful observation of patients with limited small cell lung cancer instead of the PCI-prospective, multi-center one-arm study.
    BMC Cancer. 2020;20:231.
    PubMed     Abstract available


    February 2020
  260. CHO I, Lee H, Yoon SE, Ryu KJ, et al
    Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
    BMC Cancer. 2020;20:120.
    PubMed     Abstract available


  261. TREUTWEIN M, Steger F, Loeschel R, Koelbl O, et al
    The influence of radiotherapy techniques on the plan quality and on the risk of secondary tumors in patients with pituitary adenoma.
    BMC Cancer. 2020;20:88.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.